Double-Punch cell therapy aims to outsmart tough blood cancers
NCT ID NCT04162353
Summary
This early-stage study is testing a new type of cell therapy designed to attack two different targets on cancer cells. It is for patients with multiple myeloma or a type of lymphoma that has come back or stopped responding to standard treatments. The main goal is to see if this two-target approach is safe and tolerable for patients who have no other treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chengdu Military General Hospital
RECRUITINGChengdu, Sichuan, China
Contact Email: •••••@•••••
-
Peking University Shenzhen Hospital, China
RECRUITINGShenzhen, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.